BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, March 4, 2026
Breaking News: Moderna to pay up to $2.25B to settle COVID-19 patents caseBreaking News: Trump administration impacts continue to roil the life sciences sector
Home » Topics » BioWorld Asia

BioWorld Asia
BioWorld Asia RSS Feed RSS

IPO stock market ticker

Caliway’s $206M IPO marks largest in Taiwan’s biotech history

Oct. 8, 2024
By Tamra Sami
Taiwan’s Caliway Biopharmaceuticals Co. Ltd. raised NT$6.4 billion (US$206 million) in its IPO on the Taipei Stock Exchange, making it the largest IPO in Taiwan’s biotech industry history and valuing the company at nearly $3 billion following the listing.
Read More

Astrazeneca picks up early stage Lp(a) disruptor in $2B CSPC deal

Oct. 8, 2024
By Jennifer Boggs
Astrazeneca plc is adding a preclinical-stage candidate to its cardiovascular pipeline via a potentially $2 billion licensing agreement with CSPC Pharmaceutical Group Ltd., which includes a $100 million up-front payment for rights to YS-2302018, an oral Lp(a) disruptor. It’s an impressive figure for such an early program, but the Cambridge, U.K.-based pharma hailed the small molecule’s potential against a range of indications, both alone and in combination regimens that could include PCSK9 inhibitor AZD-0780.
Read More
Brain and DNA

Aviadobio, Astellas ink $2B+ frontotemporal dementia gene therapy deal

Oct. 8, 2024
By Nuala Moran
Aviadobio Ltd. has entered a potential $2.18 billion license and commercialization agreement for its frontotemporal dementia gene therapy, AVB-101, with Astellas Pharma Inc. Astellas is making a $20 million equity investment in London-based Aviadobio and will pay up to $30 million up front in advance of deciding whether or not to exercise the exclusive option to worldwide rights.
Read More

Wuhan YZY, CTTQ ink $143M China bispecific antibody deal

Oct. 8, 2024
By Tamra Sami
Wuhan YZY Biopharma Co. Ltd. is out-licensing lead candidate M-701, a CD3/EpCAM bispecific antibody, to Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) for China rights in a deal worth up to $143 million. Under the deal, Sino Biopharmaceutical Ltd. subsidiary CTTQ is granted an exclusive license to develop, register, manufacture and commercialize M-701 within mainland China.
Read More

Regulatory actions for October 8, 2024

Oct. 8, 2024
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Astrazeneca, Clinuvel, Modalis, Telix.
Read More

In the clinic for October 8, 2024

Oct. 8, 2024
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Kazia, CSL, Henlius,
Read More

Financings for October 8, 2024

Oct. 8, 2024
Biopharmas in Asia-Pacific raising money in public or private financings: Merck, MIthradote, Orum, Poxel, Sumitomo, Taho.
Read More

Other news to note for October 8, 2024

Oct. 8, 2024
Biopharma happenings in Asia-Pacific including deals and partnerships, grants, preclinical data and other news in brief: ATF, Bionomics, Biotheus, Cenra, Combiphar, Curon, D-Wave Quantum, Hyloris, Immunoprecise Antibodies, Japan Tobacco, Leadermed, Liquidia, Merck, Moderna, Neurphoria, Mochida, Nxera Pharma, Pharmosa Shinogi, Xizang Weixinkang.
Read More

Appointments and advancements for October 8, 2024

Oct. 8, 2024
New hires and promotions in biopharma in Asia-Pacific, including: Engeneic, Nxera.
Read More
Illustration of Victor Ambros and Gary Ruvkun
Biomarkers

Two win Nobel for microRNA work

Oct. 8, 2024
By Mar de Miguel
Research into the regulation of gene expression experienced a significant breakthrough with the discovery of microRNA, small RNA molecules that do not code for proteins but control their translation. This finding has earned its discoverers – Victor Ambros and Gary Ruvkun – the 2024 Nobel Prize in Physiology or Medicine “for the discovery of microRNA and its role in post-transcriptional gene regulation.”
Read More
Previous 1 2 … 93 94 95 96 97 98 99 100 101 … 1469 1470 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • Brain and virus with chromosome

    CROI 2026: Neurodegeneration, the challenge of aging with HIV

    BioWorld
    Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 3, 2026
  • Depression concept with human, broken brain and heavy rain

    CROI 2026 highlights depression and cognitive vulnerability in HIV

    BioWorld
    The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
  • University of Southern California reports new MAPT aggregation inhibitors

    BioWorld Science
    The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing